FDA 公布广西玉林制药集团 483 检查报告,列 8 项观察
FDA 483:广西玉林制药集团有限责任公司!
FDA 对广西玉林制药集团有限责任公司(FEI 1000589993)的 483 检查报告列出 8 项观察,检查日期为2025年3月17日至21日,签发日期为2025年3月21日。
材料逐条译出 483 的八项观察,涵盖放行检测、方法验证、稳定性与偏差处理,可供比对检查关注点。
近日,FDA 公布了康臣药业集团成员 广西玉林制药集团有限责任公司(广西玉林市城站路1号,FEI 1000589993)的483检查报告,列8项观察,如下:
八项观察里最重的一项在第5项:2022年9月收到第三方对 4 号罐(设备号 130301011)的停用通知,企业没有开偏差、也没有评估这台设备还能不能用,接着用——一直用到2023年4月才换掉,这七个月里生产的批次销往了美国市场。
其余几项分布得很开:OTC 药品放行前不测活性成分含量;检测方法未验证、内控标准与《中国药典》不一致;稳定性考察没有书面方案;生产工艺没按批次量验证;清洁验证不足;原料供应商的例行审计记录停在2016年;标签不做平衡。
图1 FDA 483 原件第1页(FEI 1000589993,2025年3月21日签发,共7页)
Inspection Details
检查基本信息
Firm / 企业
Guangxi Yulin Pharmaceutical Group Co. Ltd. 广西玉林制药集团有限责任公司
Address / 地址
1 Chengzhan Road(玉林市城站路1号)
City / 城市
Yulin, Guangxi, 537001 China(中国广西玉林,537001)
FEI Number / FEI 号
1000589993
Dates of Inspection / 检查日期
2025年3月17日–3月21日
Type Establishment Inspected / 受检设施类型
OTC Manufacturer(非处方药生产商)
Issued To / 收件人
Mr. Guo Guorong (Chairman & GM)(郭国荣,董事长兼总经理)
District Office / 地区办公室
12420 Parklawn Drive, Room 2032, Rockville, MD 20857
Issued / 签发
2025年3月21日 检查员:Gavin T. Cua(CSO);Crystal Monroy(CSO)
说明:原件未印法规条款号。八项观察的标题分别对应 21 CFR 211.165(a)、211.160(b)、211.166(a)、211.100(a)、211.192、211.67(a)、211.100(b)、211.125(a),属编者对应,见文末译注①。
OBSERVATION 1
观察1:放行前的检测(211.165(a))
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
药品分销放行时的检测,未包括在放行前对各活性成分的鉴别与效力是否符合要求作出适当的实验室判定。
Specifically,
具体而言,
a) Your firm does not perform analytical testing to determine the concentrations of (b)(4) (b)(4) active ingredients in the (b)(4) finished OTC drug product.(b)(4) batches of this drug product were distributed to the US in July 2023.
a) 贵公司未进行含量分析检测,以测定 (b)(4) 成品 OTC 药品中 (b)(4) (b)(4) 活性成分的浓度。该药品有 (b)(4) 个批次于2023年7月销往美国。
b) Percentage concentrations of the (b)(4) active ingredients in finished dosage units of the (b)(4) OTC drug product have not been determined. The finished product test results of the (b)(4) active ingredient assay are reported in units of milligrams per milliliter (mg/mL) and no evaluation has been made to assess if this concentration meets the (b)(4) % concentration label claim for (b)(4) active ingredients. For example, (b)(4) batch (b)(4) (b)(4) mL packaging size) has finished product (b)(4) assay test results reported as (b)(4) (b)(4) mg/mL, respectively.(b)(4) batches of (b)(4) have been distributed to the US since December 2020.
b) (b)(4) 成品 OTC 药品各剂量单位中 (b)(4) 活性成分的百分比浓度,尚未测定。该 (b)(4) 活性成分含量测定的成品检测结果,以毫克每毫升(mg/mL)为单位报告,且未做任何评估,以判断该浓度是否符合(b)(4) 活性成分 (b)(4)% 的标签标示浓度。例如,(b)(4) 批次 (b)(4)((b)(4) mL 包装规格)的成品 (b)(4) 含量测定结果分别报告为 (b)(4) (b)(4) mg/mL。自2020年12月起,已有 (b)(4) 个批次 (b)(4) 销往美国。
OBSERVATION 2
观察2:实验室控制(211.160(b))
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards, and test procedures designed to assure that components and drug products conform to appropriate standards of identity, strength, quality and purity.
实验室控制未包括建立科学合理且适当的质量标准、规范和检测方法,以确保组分与药品符合适当的鉴别、效力、质量和纯度标准。
Specifically,
具体而言,
a) Your firm has not validated or verified all the component, intermediate/in-process, and finished product analytical test methods performed on (b)(4) OTC drug products. Test methods including but not limited to the following, have not been validated or verified:
a) 贵公司未对 (b)(4) OTC 药品所实施的全部组分、中间体/过程物料及成品分析检测方法进行验证或确认。包括但不限于以下方法,均未经验证或确认:
Active ingredient raw material component testing:
活性成分原料组分检测:
○ (b)(4) assay [gas chromatography (GC)]
○ (b)(4) 含量测定〔气相色谱(GC)〕
○ (b)(4) identification test (UV-visible spectroscopy and infrared spectroscopy)
○ (b)(4) 鉴别试验(紫外-可见光谱与红外光谱)
○ (b)(4) related substances test (GC)
○ (b)(4) 有关物质检测(GC)
(b)(4) intermediate/in-process testing:
(b)(4) 中间体/过程物料检测:
○ (b)(4) assay (b)(4) (b)(4) (b)(4) finished product testing:
○ (b)(4) 含量测定 (b)(4) (b)(4) (b)(4) 成品检测:
○ (b)(4) assay
○ (b)(4) 含量测定
○ (b)(4)
○ (b)(4)
b) Your firm follows the Chinese Pharmacopoeia (ChP) for the test procedures, specifications, and reference standards used in component, intermediate/in-process, and finished product testing of the (b)(4) OTC drug products distributed to the US. In accordance with the ChP:
b) 对销往美国的 (b)(4) OTC 药品,其组分、中间体/过程物料与成品检测所用的检测方法、质量标准与对照品,贵公司遵循《中国药典》(ChP)。按 ChP 的要求:
The acceptance criteria for the assay of (b)(4) active ingredients in finished product (b)(4) is, "...contains no less than (b)(4) mg per mL" for each individual active ingredient (your firm's internal standard is, "...no less than (b)(4) mg/mL").
(b)(4) 成品中 (b)(4) 活性成分含量测定的接受标准为:各单一活性成分“……每毫升不少于 (b)(4) mg”(贵公司内控标准为“……不少于 (b)(4) mg/mL”)。
The identification tests for component testing of (b)(4) active ingredient are performed through colorimetric analysis rather than gas chromatography.
(b)(4) 活性成分组分检测的鉴别试验,采用比色分析而非气相色谱进行。
Component testing for (b)(4) active ingredient assay has an acceptance criteria of (b)(4) %-(b)(4) %.
(b)(4) 活性成分含量测定的组分检测,接受标准为 (b)(4)%–(b)(4)%。
c) The method validation performed on the finished product in-house test method of (b)(4) assay by gas chromatography for (b)(4) OTC drug product is inadequate:
c) 对 (b)(4) OTC 药品成品、(b)(4) 含量测定气相色谱内控方法所做的方法验证不充分:
Accuracy: It is unclear how the results of percentage of the recovery of the known added amount or (b)(4) in the sample injections were calculated.
准确度:已知加入量的回收率百分比,或样品进样中 (b)(4) 的结果如何计算,并不清楚。
Specificity: Assay test results are reported as a ratio of mg/mL with no evaluation or calculation of the percentage concentration of the (b)(4) active ingredients. As such, this test method does not provide meaningful test results providing information on the potency of the analytes in these samples.
专属性:含量测定结果以 mg/mL 的比值报告,既未评估也未计算 (b)(4) 活性成分的百分比浓度。因此,该方法无法提供有意义的检测结果,也就无法反映这些样品中被分析物的效价。
d) System suitability testing is inadequate for the assay of (b)(4) active ingredients by gas chromatography in raw material component testing and in the assay of these active ingredients in finished product testing of (b)(4):
d) 在原料组分检测中用气相色谱测定 (b)(4) 活性成分、以及在 (b)(4) 成品检测中测定这些活性成分时,系统适用性试验不充分:
There is no blank injection.
没有空白进样。
The percent relative standard deviation is not calculated for the peak areas of the (b)(4) (b)(4) reference standard injections.
未对 (b)(4) (b)(4) 对照品进样的峰面积计算相对标准偏差百分比。
System suitability testing in the method validation for (b)(4) assay by gas chromatography in (b)(4) finished product testing consists of (b)(4) reference standard injections, however, testing of finished product batches consists of (b)(4) reference standard injections.
(b)(4) 成品检测中 (b)(4) 含量测定气相色谱的方法验证,其系统适用性试验为 (b)(4) 针对照品进样;然而成品批次检测只有 (b)(4) 针对照品进样。
e) Your firm lacks controls to ensure data integrity is implemented and maintained over analytical instruments and corresponding analytical software. For example:
e) 贵公司缺乏控制措施,以确保分析仪器及相应分析软件的数据完整性得到实施与维持。例如:
There is no audit trail feature for the IRSolution software used in infrared (IR) spectroscopy.
红外(IR)光谱所用的 IRSolution 软件没有审计追踪功能。
There is no audit trail feature for the UVProbe software used in UV-Vis spectroscopy. Both analytical software systems are used for the component identification tests of the (b)(4) active ingredient.
紫外-可见光谱所用的 UVProbe 软件没有审计追踪功能。这两套分析软件系统均用于 (b)(4) 活性成分的组分鉴别试验。
Raw data electronic files generated from the IR and UV-Vis software and saved locally on to the computer system can be deleted by QC personnel.
由 IR 与 UV-Vis 软件生成、保存在计算机系统本地的原始数据电子文件,可被 QC 人员删除。
There is no review of the audit trail of the gas chromatography OpenLab software after completion of finished product testing and prior to finished product approval and release of each batch of (b)(4) OTC drug product. This software is used for the assay of (b)(4) active ingredients in finished product testing.
在每个批次 (b)(4) OTC 药品的成品检测完成之后、成品批准放行之前,未对气相色谱 OpenLab 软件的审计追踪进行复核。该软件用于成品检测中 (b)(4) 活性成分的含量测定。
There is no documentation or record of the review and comparison of electronic raw data to the printed, physical copy of the data.
没有文件或记录,用以证明已将电子原始数据与打印的纸质副本进行复核和比对。
OBSERVATION 3
观察3:稳定性考察(211.166(a))
There is no written testing program designed to assess the stability characteristics of drug products.
没有为评估药品稳定性特征而设计的书面检测方案。
Specifically,
具体而言,
(A) You have failed to establish how your stability testing methods are stability indicating. You do not have data to show your stability test methods meet the appropriate identity, strength, and quality attributes to support the (b)(4) shelf life of your OTC (b)(4) products, (b)(4) (b)(4) (b)(4).
(A) 贵公司未能确立其稳定性检测方法具备稳定性指示能力。贵公司没有数据表明其稳定性检测方法能满足适当的鉴别、效力与质量属性,以支持 OTC (b)(4) 产品 (b)(4) (b)(4) (b)(4) 的 (b)(4) 有效期。
(B) Microbial content and identification testing are not performed at appropriate intervals during your stability studies for your OTC (b)(4) (b)(4) (b)(4) products. Microbiological and identity testing is only performed at the beginning of your stability study at the end of your study at (b)(4) (b)(4) (b)(4). You do not have scientific rational to support this test frequency.
(B) 在 OTC (b)(4) (b)(4) (b)(4) 产品的稳定性研究中,微生物限度与鉴别检测未按适当间隔进行。微生物与鉴别检测仅在稳定性研究的开始时、(研究结束时)于 (b)(4) (b)(4) (b)(4) 进行。贵公司没有科学依据支持这一检测频次。
(C) Stability testing for (b)(4) (b)(4) (b)(4) does not testing for the active contents and you do not have scientific rational to justify not performing this test.
(C) 对 (b)(4) (b)(4) (b)(4) 的稳定性考察,未对活性成分含量进行检测,贵公司也没有科学依据说明为何不做该项检测。
OBSERVATION 4
观察4:生产与工艺控制程序(211.100(a))
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
贵公司未能建立适当的书面生产与工艺控制程序,以确保药品具备其所声称或标示的鉴别、效力、纯度与质量。
Specifically,
具体而言,
a) The production processes for the (b)(4) OTC drug products have not been validated for a specific batch size. The validated batch size for (b)(4) (b)(4) is (b)(4)
a) (b)(4) OTC 药品的生产工艺未针对特定批次量进行验证。用于 (b)(4) (b)(4) 的已验证批次量为 (b)(4)
b) Your firm's calculation for percentage of theoretical yield has an acceptance criteria of (b)(4) %. The theoretical yield is based on a batch size of (b)(4) which can be exceeded by the actual yield due to the variation of production batch sizes.
b) 贵公司的理论收率百分比计算,接受标准为 (b)(4)%。理论收率基于 (b)(4) 的批次量计算,而由于生产批次量的变化,实际收率可能超出该批次量。
OBSERVATION 5
观察5:偏差调查(211.192)
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
对任何无法解释的差异,未进行彻底审查,无论该批次是否已经分销。
Specifically,
具体而言,
You did not open a deviation investigation following issues identified with your (b)(4) equipment. In September 2022, you received a third-party suspension notification for your (b)(4) (b)(4) tank 4, equipment ID 130301011. However, upon receipt of this notification you failed to open a deviation to establish if the equipment was adequate for use and continued using tank 4 equipment ID 130301011 until it was replaced in April 2023. From September 2022 to April 2023, you manufactured approximately (b)(4) batches of OTC (b)(4) (b)(4) which were distributed to the U.S. market.
在发现 (b)(4) 设备问题后,贵公司没有启动偏差调查。2022年9月,贵公司收到第三方针对 (b)(4) (b)(4) 4号罐(设备号 130301011)的停用通知。然而,收到该通知后,贵公司未启动偏差以确认该设备是否可以继续使用,而是继续使用 4 号罐(设备号 130301011),直至2023年4月将其更换。2022年9月至2023年4月期间,贵公司生产了约 (b)(4) 个批次的 OTC (b)(4) (b)(4),这些批次销往了美国市场。
In addition, no preventive actions were assessed or proposed for deviation PC-20250201 in which an unplanned power outage led to a loss of power to your firm's stability chambers.
此外,对于偏差 PC-20250201——一次非计划停电导致贵公司稳定性试验箱断电——既未评估也未提出预防措施。
图2 原件第5页:第5项观察(4号罐的停用通知与七个月的生产)
OBSERVATION 6
观察6:设备清洁(211.67(a))
Equipment and utensils are not cleaned at appropriate intervals to prevent contamination that would alter the safety, identity, strength, or purity of the drug product.
设备与器具未按适当间隔清洁,以防止可能改变药品安全性、鉴别、效力或纯度的污染。
Specifically,
具体而言,
Your firms cleaning validation studies to justify the cleaning in your (b)(4) preparation system are inadequate. For example,
贵公司用以支持 (b)(4) 配制系统清洁的清洁验证研究不充分。例如:
(A) You do not have records to show you have validated the cleaning procedures for extended clean hold times.
(A) 贵公司没有记录表明,已对延长清洁保持时间的清洁程序进行验证。
(B) You failed to establish how the methods used for your cleaning validation studies are adequate to detect the number of residual contaminants in your rinse samples.
(B) 贵公司未能确立:清洁验证研究所用的方法,足以检出淋洗样中残留污染物的数量。
OBSERVATION 7
观察7:生产与工艺控制程序的执行(211.100(b))
Written production and process control procedures are not followed in the execution of production and process control functions and documented at the time of performance.
在生产与工艺控制职能的执行过程中,未遵守书面的生产与工艺控制程序,也未在操作发生时同步记录。
Specifically,
具体而言,
(A) Your firm failed to maintain records for routine supplier audits of your active pharmaceutical ingredient supplier. Records for the last (b)(4) supplier audits for your (b)(4) active pharmaceutical ingredient supplier could not be found. The last record your facility has of a routine supplier audit was dated 2016. (b)(4) (b)(4) is one of the active pharmaceutical ingredients for your (b)(4) (b)(4) (b)(4) drug products.
(A) 贵公司未能保存对原料药供应商进行例行审计的记录。贵公司 (b)(4) 原料药供应商最近 (b)(4) 次供应商审计的记录无法找到。该厂区留存的最近一次例行供应商审计记录,日期为2016年。(b)(4) (b)(4) 是贵公司 (b)(4) (b)(4) (b)(4) 药品的原料药之一。
(B) Your quality unit failed to implement appropriate change control procedures following changes to your supplier qualification process. For example, you changed your procedures for conducting routine supplier audits. However, these changes were not included in a change control process, and you do not have justification for why these changes were not incorporated into a change control.
(B) 在供应商资质确认流程发生变更后,贵公司质量部门未能实施适当的变更控制程序。例如,贵公司修改了开展例行供应商审计的程序,但这些变更未纳入变更控制流程,贵公司也没有理由说明为何未将其纳入变更控制。
OBSERVATION 8
观察8:标签发放控制(211.125(a))
Strict control is not exercised over labeling issued for use in drug product labeling operations.
对药品贴标操作中发放使用的标签,未实施严格的控制。
Specifically,
具体而言,
a) There is no label reconciliation in the packaging record for the (b)(4) OTC drug product.
a) (b)(4) OTC 药品的包装记录中,没有标签平衡(标签领用、使用与退库数量的核对)。
b) Reconciliation of labeling materials is inadequate as the starting quantity of packaging and labeling materials is not always confirmed to be accurate, therefore, resulting in inaccurate calculations for reconciliation.
b) 标签物料的平衡不充分:包装与标签物料的起始数量并不总是经确认为准确,因而导致平衡计算不准确。
来源:制药经理人 · mp.weixin.qq.com